

Duchenne and Becker muscular dystrophy

Description

Muscular dystrophies are a group of genetic conditions characterized by progressive muscle weakness and wasting (atrophy). The Duchenne and Becker types of muscular dystrophy are two related conditions that primarily affect skeletal muscles, which are used for movement, and heart (cardiac) muscle. These forms of muscular dystrophy occur almost exclusively in males.

Duchenne and Becker muscular dystrophies have similar signs and symptoms and are caused by different mutations in the same gene. The two conditions differ in their severity, age of onset, and rate of progression. In boys with Duchenne muscular dystrophy, muscle weakness tends to appear in early childhood and worsen rapidly. Affected children may have delayed motor skills, such as sitting, standing, and walking. They are usually wheelchair-dependent by adolescence. The signs and symptoms of Becker muscular dystrophy are usually milder and more varied. In most cases, muscle weakness becomes apparent later in childhood or in adolescence and worsens at a much slower rate.

Both the Duchenne and Becker forms of muscular dystrophy are associated with a heart condition called cardiomyopathy. This form of heart disease weakens the cardiac muscle, preventing the heart from pumping blood efficiently. In both Duchenne and Becker muscular dystrophy, cardiomyopathy typically begins in adolescence. Later, the heart muscle becomes enlarged, and the heart problems develop into a condition known as dilated cardiomyopathy. Signs and symptoms of dilated cardiomyopathy can include an irregular heartbeat (arrhythmia), shortness of breath, extreme tiredness (fatigue), and swelling of the legs and feet. These heart problems worsen rapidly and become life-threatening in most cases. Males with Duchenne muscular dystrophy typically live into their twenties, while males with Becker muscular dystrophy can survive into their forties or beyond.

A related condition called X-linked dilated cardiomyopathy is a form of heart disease caused by mutations in the same gene as Duchenne and Becker muscular dystrophy, and it is sometimes classified as subclinical Becker muscular dystrophy. People with X-linked dilated cardiomyopathy typically do not have any skeletal muscle weakness or wasting, although they may have subtle changes in their skeletal muscle cells that are detectable through laboratory testing.

Frequency

Duchenne and Becker muscular dystrophies together affect 1 in 3,500 to 5,000 newborn males worldwide. Between 400 and 600 boys in the United States are born with these conditions each year.

Causes

Mutations in the *DMD* gene cause the Duchenne and Becker forms of muscular dystrophy. The *DMD* gene provides instructions for making a protein called dystrophin. This protein is located primarily in skeletal and cardiac muscle, where it helps stabilize and protect muscle fibers. Dystrophin may also play a role in chemical signaling within cells.

Mutations in the *DMD* gene alter the structure or function of dystrophin or prevent any functional dystrophin from being produced. Muscle cells without enough of this protein become damaged as muscles repeatedly contract and relax with use. The damaged fibers weaken and die over time, leading to the muscle weakness and heart problems characteristic of Duchenne and Becker muscular dystrophies. Mutations that lead to an abnormal version of dystrophin that retains some function usually cause Becker muscular dystrophy, while mutations that prevent the production of any functional dystrophin tend to cause Duchenne muscular dystrophy.

Because Duchenne and Becker muscular dystrophies result from faulty or missing dystrophin, these conditions are classified as dystrophinopathies.

[Learn more about the gene associated with Duchenne and Becker muscular dystrophy](#)

- DMD

Inheritance

This condition is inherited in an X-linked recessive pattern. The gene associated with this condition is located on the X chromosome, which is one of the two sex chromosomes. In males (who have only one X chromosome), one altered copy of the gene in each cell is sufficient to cause the condition. In females (who have two X chromosomes), a mutation would have to occur in both copies of the gene to cause the disorder. Because it is unlikely that females will have two altered copies of this gene, males are affected by X-linked recessive disorders much more frequently than females. A characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons.

In many cases, an affected male inherits the mutation from his mother, who carries one altered copy of the *DMD* gene. The remainder of cases probably result from new mutations in the gene in affected males and are not inherited.

In X-linked recessive inheritance, a female with one mutated copy of the gene in each cell is called a carrier. She can pass on the altered gene but usually does not

experience signs and symptoms of the disorder. Occasionally, however, females who carry a *DMD* gene mutation may have muscle weakness and cramping. These symptoms are typically milder than the severe muscle weakness and atrophy seen in affected males. Females who carry a *DMD* gene mutation also have an increased risk of developing heart abnormalities including cardiomyopathy.

Other Names for This Condition

- DBMD
- Duchenne/Becker muscular dystrophy
- Muscular dystrophy, Duchenne and Becker types
- Muscular dystrophy, pseudohypertrophic

Additional Information & Resources

Genetic Testing Information

- Genetic Testing Registry: Becker muscular dystrophy (<https://www.ncbi.nlm.nih.gov/gtr/conditions/C0917713/>)
- Genetic Testing Registry: Duchenne muscular dystrophy (<https://www.ncbi.nlm.nih.gov/gtr/conditions/C0013264/>)

Genetic and Rare Diseases Information Center

- Becker muscular dystrophy (<https://rarediseases.info.nih.gov/diseases/5900/index>)
- Duchenne muscular dystrophy (<https://rarediseases.info.nih.gov/diseases/6291/index>)

Patient Support and Advocacy Resources

- National Organization for Rare Disorders (NORD) (<https://rarediseases.org/>)

Clinical Trials

- ClinicalTrials.gov (<https://clinicaltrials.gov/search?cond=%22Duchenne and Becker muscular dystrophy%22>)

Catalog of Genes and Diseases from OMIM

- MUSCULAR DYSTROPHY, DUCHENNE TYPE; DMD (<https://omim.org/entry/310200>)
- MUSCULAR DYSTROPHY, BECKER TYPE; BMD (<https://omim.org/entry/300376>)

Scientific Articles on PubMed

- PubMed (<https://pubmed.ncbi.nlm.nih.gov/?term=%28Duchenne+muscular+dystrophy%5BMAJR%5D%29+AND+%28%28duchenne%5BTI%5D%29+OR+%28becker%5BTI%5D%29%29+AND+english%5BIa%5D+AND+human%5Bmh%5D+AND+%22Iast+360+days%22%5Bdp%5D>)

References

- Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. *Lancet Neurol*. 2010 Jan;9(1):77-93. doi:10.1016/S1474-4422(09)70271-6. Epub 2009 Nov 27. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/19945913>)
- Darras BT, Urion DK, Ghosh PS. Dystrophinopathies. 2000 Sep 5 [updated 2022 Jan 20]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. *GeneReviews*(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from <http://www.ncbi.nlm.nih.gov/books/NBK1119/> Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/20301298>)
- Deconinck N, Dan B. Pathophysiology of Duchenne muscular dystrophy: current hypotheses. *Pediatr Neurol*. 2007 Jan;36(1):1-7. doi:10.1016/j.pediatrneurol.2006.09.016. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/17162189>)
- Mah JK, Korngut L, Dykeman J, Day L, Pringsheim T, Jette N. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. *Neuromuscul Disord*. 2014 Jun;24(6):482-91. doi:10.1016/j.nmd.2014.03.008. Epub 2014 Mar 22. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/24780148>)
- Verma S, Anziska Y, Cracco J. Review of Duchenne muscular dystrophy (DMD) for the pediatricians in the community. *Clin Pediatr (Phila)*. 2010 Nov;49(11):1011-7. doi: 10.1177/0009922810378738. Epub 2010 Aug 19. No abstract available. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/20724320>)
- Wein N, Alfano L, Flanigan KM. Genetics and emerging treatments for Duchenne and Becker muscular dystrophy. *Pediatr Clin North Am*. 2015 Jun;62(3):723-42. doi:10.1016/j.pcl.2015.03.008. Epub 2015 Apr 20. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/26022172>)

Last updated November 1, 2016